National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

HARDBACK
price:$52.95
add to cart

Rights & Permissions

topleft topright

Vaccines for the 21st Century: A Tool for Decisionmaking (2000)
Institute of Medicine (IOM)

Citation Manager

. "Index." Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press, 2000.

Please select a format:

BibTeX EndNote RefMan


Page
447
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


Vaccines for the 21st Century: A Tool for Decisionmaking

Court cases, see Liability issues;

Litigation

Cuba, 343

Cystic fibrosis, 33, 42

Cytokines, 27, 374, 409–411, 415, 429–433

autoimmune disease, 36, 38, 389–392, 404–405

chlamydia, 348–349

dengue virus, 344

gonorrhea, 371

Interleukin, 27, 38, 348–349, 372, 373, 374, 388, 389, 390–394, 396, 402–403, 405–406, 409, 410, 411–412, 420, 424, 430, 432

Cytomegalovirus (CMV), 6, 19, 20, 22, 54, 87, 89, 90, 165–171

D

Death rates, 377

as assessment criterion, 27

model, analytic approach, 61–62, 66, 68, 78–79, 80–83, 86

model, detailed characterization, 95, 97–98, 100, 103–104

chlamydia, 149

Coccidiodes immitis, 159, 160, 162

dengue virus, 343

gonorrhea, 257

Helicobacter pylori, 181, 182

herpes simplex virus, 198

Histoplasma capsulatum, 207, 208

influenza virus, 225–226

malaria, 43

melanoma, 239

meningitis, 267, 268

mycobacterium tuberculosis, 252, 253, 351

parainfluenza virus, 273

polio, 24

papillomaviruses, 215

respiratory syncytial virus, 279, 281, 283

rheumatoid arthritis, 287

rotavirus, 291

streptococcus, group B, 305, 307, 309

Streptococcus pneumoniae 313, 321

see also Life expectancy; Quality-adjusted life years

Dengue hemorrhagic fever, 342–347

Dental caries, 44–45

Delivery of vaccines, 130

adults, 47–50

antigens, various, 377–381

children, 45–47

DNA vaccines, 381–386

intranasal immunization

mycobacterium tuberculosis, 354

polio, 25–26

pregnant women, 50–51

see also Noninjection routes; Utilization of vaccines; Vaccine schedules

Demographic factors, 58

see also Age factors; Immigrants; Men; Race/ethnicity; Regional factors; Travelers; Urban areas; Women

Dengue hemorrhagic fever, 8

Department of Health and Human Services, 20–21

Centers for Disease Control and Prevention, 14, 28, 50, 100

Food and Drug Administration, 14, 125, 126, 362, 367, 373, 374;

see also Licensure, vaccines

Health Care Financing Administration, 71, 106

see also National Institutes of Health; specific institutes

Developing countries, 1, 17, 127–128, 173, 355, 360

Diabetes mellitus, 6, 35, 37, 54, 67, 87, 90, 233–238, 386–389, 391, 392, 393–395, 403

Diptheria, 20, 28, 30, 46, 49

Disabilities, 63–66, 68, 78–79, 86, 89, 97–98

cognitive impairments, 62, 64–65

emotional impairments, 64–65

ethical factors, 111, 112–113, 114–115

Page
447
Front Matter (R1-R12)
Executive Summary (1-10)
Introduction (11-16)
Progress in Vaccine Development (17-38)
Considerations of Candidate Vaccines (39-52)
Overview of Analytic Approach and Results (53-92)
Review of the Analytical Model (93-108)
Ethical Considerations and Caveats (109-122)
Observations (123-132)
References (133-142)
Appendix 1: Borrelia burgdorferi (143-148)
Appendix 2: Chlamydia (149-158)
Appendix 3: Coccidioides Immitis (159-164)
Appendix 4: Cytomegalovirus (165-172)
Appendix 5: Enterotoxigenic E. coli (173-176)
Appendix 6: Epstein-Barr Virus (177-180)
Appendix 7: Helicobacter pylori (181-188)
Appendix 8: Hepatitis C (189-194)
Appendix 9: Herpes Simplex Virus (195-206)
Appendix 10: Histoplasma capsulatum (207-212)
Appendix 11: Human Paillomavirus (213-222)
Appendix 12: Influenza A and B (223-232)
Appendix 13: Insulin-Dependent Diabetes Mellitus (233-238)
Appendix 14: Melanoma (239-244)
Appendix 15: Multiple Sclerosis (245-250)
Appendix 16: Mycobacterium tuberculosis (251-256)
Appendix 17: Neisseria gonnorrhea (257-266)
Appendix 18: Neisseria meningitidis (267-272)
Appendix 19: Parainfluenza Virus (273-278)
Appendix 20: Respiratory Syncytial Virus (279-284)
Appendix 21: Rheumatoid Arthritis (285-290)
Appendix 22: Rotavirus (291-294)
Appendix 23: Shigella (295-298)
Appendix 24: Streptococcus, Group A (299-304)
Appendix 25: Streptococcus, Group B (305-312)
Appendix 26: Streptococcus pneumoniae (313-322)
Appendix 27: Information on accessing Electronic Spreadsheets (323-324)
Appendix 28: Summary of Workshops (325-434)
Appendix 29: Questions Posed to Outside Experts and List of Responders (435-442)
Index (443-460)